ESLA Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in A
ESLA Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
Story updates
12:01:27 PM UTC
SquawkNews
ESLA - Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.